Cyclic molecules as bruton's tyrosine kinase inhibitors
The present document describes novel molecules having protein tyrosine kinase inhibitory activity, and methods of synthesizing and using such compounds. More specifically, the present document describes compound of Formula (A): (Formula (A)) or a pharmaceutically acceptable salt, hydrate or solvate thereof, and methods of synthesizing and using such compounds.
1. A compound of Formula (B)
or a pharmaceutically acceptable salt, hydrate or solvate thereof, wherein:
is selected from the group consisting of:
X is:
R 5 , R 4 and R 6 are independently selected from H, C 1-12 alkyl, C 1-12 heteroalkyl, C 1-12 heterocycloalkyl, C 2-12 alkenyl, C 2-12 alkynyl, C 3-12 cycloalkyl;
L 3 is CH 2 , O, S, or NR d ;
R d is H, C 1-6 alkyl, C 3-6 cycloalkyl, aryl or heteroaryl;
Ar is an aryl or heteroaryl which is unsubstituted or substituted with one or more R e ;
R e is independently chosen from halogen, C 1-12 alkyl, C 2-12 alkenyl, C 2-12 alkynyl, C 3-12 cycloalkyl, C 6-12 aryl, a 3-12 membered heteroalicyclic ring, a 5-12 membered heteroaryl ring, —S(O) m R d , —S(O) 2 NR d R d , —S(O) 2 OR d , SF 5 , —CN, —NO 2 , —NR d R d , —C(O)R d , —OC(O)R d , —O(CR d R d ) n R d , —NR d C(O)R d , —(CR d R d ) n C(O)OR 4 , —(CR d R d ) n OR 4 , —(CR d R d ) n C(O)NR d R d , —(CR d R d ) n NCR d R d , —C(═NR d )NR d R d , —NR d C(O)NR d R d , —NR d S(O) 2 R d or —C(O)NR d R d , wherein each hydrogen in R d is unsubstituted or substituted by R f ;
wherein two R d on the same atom are unconnected or connected to form a carbocyclic ring, or
two R d on the same atom are unconnected or connected to form a carbocyclic ring in which one or more carbon ring atoms are replaced with one or more O, S, S(O), S(O) 2 , C(O), C(S) and NR d ;
n is selected from 1 to 6;
R f is independently chosen from halogen, C 1-12 alkyl, C 2-12 alkenyl, C 2-12 alkynyl, C 3-12 cycloalkyl, C 6-12 aryl, a 3-12 membered heteroalicyclic ring, a 5-12 membered heteroaryl ring, —NH 2 , —CN, —OH, —O—C 1-12 alkyl, —O—(CH 2 ) n C 3-12 cycloalkyl, —O—(CH 2 ) n C 6-12 aryl, —O—(CH 2 ) n (3-12 membered heteroalicyclic ring) or —O—(CH 2 ) n (5-12 membered heteroaryl ring); and
two R e on adjacent atoms are unconnected or connected to form a C 6-12 aryl ring, a 5-12 membered heteroaryl ring, a C 5-20 cycloalkyl ring or a 5-20 membered heteroalicyclic ring, or
two R e on adjacent atoms are unconnected or connected or combined to form a C 6-12 aryl ring, a 5-12 membered heteroaryl ring, a C 5-20 cycloalkyl ring or a 5-20 membered heteroalicyclic ring which contains one or more heteroatom selected from O, NR d , S.
2. The compound of claim 1 , wherein the compound is:
1-(6-(4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one;
1-(2-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-7-azaspiro[3.5]nonan-7-yl)prop-2-en-1-one;
1-(7-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-2-azaspiro[3.5]nonan-2-yl)prop-2-en-1-one; or
1-(2-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-6-azaspiro[3.5]nonan-6-yl)prop-2-en-1-one.
3. A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.
4. A pharmaceutical composition comprising a compound of claim 1 in combination with an anti-cancer agent selected from cytotoxic agents, antimitotic agents, anti-metabolites, proteasome inhibitors, HDAC inhibitors, a kinase inhibitor, or combination thereof.
5. A method of treating rheumatoid arthritis comprising administering a therapeutically effective amount of a compound of claim 1 to an individual in need thereof.
6. A method of treating rheumatoid arthritis comprising administering a therapeutically effective amount of a compound of claim 1 together with radiotherapy to an individual in need thereof.